New hope for transplant patients: Low-Dose IL-2 tames chronic GVHD

NCT ID NCT01366092

Ongoing Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times

Summary

This study tested a daily low-dose injection of IL-2 in 35 people with chronic graft-versus-host disease (cGVHD) that did not respond to steroids. cGVHD is a complication after a stem cell or bone marrow transplant where the donor's immune cells attack the recipient's body. The goal was to see if IL-2 could help control the disease and allow patients to reduce their steroid use. The treatment aims to manage symptoms and improve quality of life, but it is not a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02214, United States
Massachusetts General Hospital

Boston, Massachusetts, 02214, United States

Conditions

Explore the condition pages connected to this study.

CHRONIC GRAFT VERSUS HOST DISEASE